First AD

Second AD

Influence of TLS Risk and Patient Preferences on Treatment Selection in Relapsed/Refractory CLL

Video content above is prompted by the following:

How do you assess patients for potential risk of TLS? How does this impact your treatment choice for a non-covalent BTKi over a venetoclax-based regimen?

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies

Panelists discuss how they evaluate patients for tumor lysis syndrome (TLS) risk, considering factors such as tumor burden, renal function, and prior therapies, and how this assessment influences their decision between prescribing a non-covalent BTK inhibitor or a venetoclax-based regimen for chronic lymphocytic leukemia treatment.

The Current Treatment Landscape for R/R CLL